Lyell Immunopharma, Inc. Share Price & Technical Analysis
LYEL · $18.19 (-4.36%)
Healthcare / Biotechnology
$18.19
-4.36%
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-12% return in May, 25% avg return in past 3 year May month.
-54% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -23% | 0% | -16% | -2% | -12% | – | – | – | – | – | – | – | -54% |
| 25 | -8% | 23% | -23% | -9% | -12% | 9% | 33% | -4% | 46% | 1% | 42% | 26% | 124% |
| 24 | -6% | 59% | -24% | -4% | 27% | -48% | 13% | -10% | -5% | -29% | -3% | -32% | -64% |
| 23 | -6% | -34% | 8% | -14% | 59% | 0% | -8% | -17% | -38% | 13% | 4% | 12% | -22% |
| 22 | -26% | 27% | -31% | -1% | -18% | 57% | -15% | 17% | 11% | -22% | -31% | -17% | -47% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$439.85M
P/E ratio
—
52W high
$45.00
52W low
$7.65
Volume
7,926
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Lyell Immunopharma, Inc. share price today?
- Lyell Immunopharma, Inc. (LYEL) last traded around $18.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LYEL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LYEL. Download the app for real-time alerts.
- How can I analyze Lyell Immunopharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.